Circulating tumor DNA as a prognostic biomarker in adjuvant nivolumab therapy for high-risk muscle-invasive urothelial carcinoma: insights from CheckMate 274 and beyond.

Transl Androl Urol · 2026 · PMC13184276 · PMID 42164377

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a favorable trendno p-value reported

While 5-year OS showed a favorable trend (HR 0.83, 95% CI: 0.67–1.02), statistical significance was not achieved.

also in 1,335 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.